Topics:
Gastrointestinal Cancers • Medical Oncology
What is your treatment approach for a MSS metastatic colorectal cancer patient who has progressed on FOLFOX and FOLFIRI?
Do you have a preference for Regorafenib or Lonsurf or do you refer to clinical trials immediately given the known low response rates to these drugs?
Answer from: Medical Oncologist at Academic Institution
If the patient is RAS/BRAF wildtype, then I would pursue anti-EGFR antibody-based therapy. If the patient has KRAS mutant colorectal cancer and continues to have a good performance status, then I would pursue clinical trials if possible. Many of the clinical trials in this space are phase...
Sign in or Register to read more